Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Clinical trial NCT06697301 · RECRUITING
Trial details
- NCT number
- NCT06697301
- Sponsor
- Eikon Therapeutics
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-22
- Primary completion
- 2035-12-01
- Enrollment
- 740
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.